These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 37467796)

  • 1. Treatment outcomes in major depressive disorder in patients with comorbid alcohol use disorder: A STAR*D analysis.
    Tang VM; Yu D; Weissman CR; Jones BDM; Wang G; Sloan ME; Blumberger DM; Daskalakis ZJ; Le Foll B; Voineskos D
    J Affect Disord; 2023 Oct; 339():691-697. PubMed ID: 37467796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.
    Fava M; Rush AJ; Alpert JE; Balasubramani GK; Wisniewski SR; Carmin CN; Biggs MM; Zisook S; Leuchter A; Howland R; Warden D; Trivedi MH
    Am J Psychiatry; 2008 Mar; 165(3):342-51. PubMed ID: 18172020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study's patient-level data with fidelity to the original research protocol.
    Pigott HE; Kim T; Xu C; Kirsch I; Amsterdam J
    BMJ Open; 2023 Jul; 13(7):e063095. PubMed ID: 37491091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of comorbid alcohol use disorder on treatment response of depressive patients.
    Hashimoto E; Tayama M; Ishikawa H; Yamamoto M; Saito T
    J Neural Transm (Vienna); 2015 Feb; 122(2):301-6. PubMed ID: 24928545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, tolerability, and acceptability of bupropion for major depressive disorder: a meta-analysis of randomized-controlled trials comparison with venlafaxine.
    Maneeton N; Maneeton B; Eurviriyanukul K; Srisurapanont M
    Drug Des Devel Ther; 2013; 7():1053-62. PubMed ID: 24101861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of the effectiveness of an early medication change strategy in patients with major depressive disorder.
    Dreimüller N; Wagner S; Engel A; Braus DF; Roll SC; Elsner S; Tadić A; Lieb K
    BMC Psychiatry; 2019 Jan; 19(1):24. PubMed ID: 30642308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substance use disorder comorbidity in major depressive disorder: an exploratory analysis of the Sequenced Treatment Alternatives to Relieve Depression cohort.
    Davis LL; Rush JA; Wisniewski SR; Rice K; Cassano P; Jewell ME; Biggs MM; Shores-Wilson K; Balasubramani GK; Husain MM; Quitkin FM; McGrath PJ
    Compr Psychiatry; 2005; 46(2):81-9. PubMed ID: 15723023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STAR*D: revising conventional wisdom.
    Rush AJ; Warden D; Wisniewski SR; Fava M; Trivedi MH; Gaynes BN; Nierenberg AA
    CNS Drugs; 2009 Aug; 23(8):627-47. PubMed ID: 19594193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comorbid anxiety in late-life depression: Relationship with remission and suicidal ideation on venlafaxine treatment.
    Saade YM; Nicol G; Lenze EJ; Miller JP; Yingling M; Wetherell JL; Reynolds CF; Mulsant BH
    Depress Anxiety; 2019 Dec; 36(12):1125-1134. PubMed ID: 31682328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure.
    Ahmed AT; Biernacka JM; Jenkins G; Rush AJ; Shinozaki G; Veldic M; Kung S; Bobo WV; Hall-Flavin DK; Weinshilboum RM; Wang L; Frye MA
    J Affect Disord; 2019 Mar; 246():62-68. PubMed ID: 30578947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach.
    Chekroud AM; Gueorguieva R; Krumholz HM; Trivedi MH; Krystal JH; McCarthy G
    JAMA Psychiatry; 2017 Apr; 74(4):370-378. PubMed ID: 28241180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What to Expect When Switching to a Second Antidepressant Medication Following an Ineffective Initial SSRI: A Report From the Randomized Clinical STAR*D Study.
    Rush AJ; South C; Jha MK; Jain SB; Trivedi MH
    J Clin Psychiatry; 2020 Aug; 81(5):. PubMed ID: 32780949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes.
    Davis LL; Wisniewski SR; Howland RH; Trivedi MH; Husain MM; Fava M; McGrath PJ; Balasubramani GK; Warden D; Rush AJ
    Drug Alcohol Depend; 2010 Mar; 107(2-3):161-70. PubMed ID: 19945804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized, Double-Blind, Placebo-Controlled Pilot Trial of the Acute Antisuicidal and Antidepressant Effects of Intranasal (R,S)-Ketamine in Severe Unipolar and Bipolar Depression With and Without Comorbid Alcohol Use Disorder.
    Jones GH; Vecera CM; Ruiz AC; Wu HE; McInturff SI; Orejarena MJ; Smith KA; Soares JC; Zarate CA; Lane SD; Machado-Vieira R
    J Clin Psychiatry; 2024 Apr; 85(2):. PubMed ID: 38696221
    [No Abstract]   [Full Text] [Related]  

  • 15. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials.
    Iovieno N; Tedeschini E; Bentley KH; Evins AE; Papakostas GI
    J Clin Psychiatry; 2011 Aug; 72(8):1144-51. PubMed ID: 21536001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Patient-reported Outcomes of Quality of Life and Functioning Before and After Treatment of Major Depressive Disorder Comorbid With Alcohol Use Disorders.
    Danovitch I; Steiner AJ; Kazdan A; Goldenberg M; Haglund M; Mirocha J; Collison K; Vanle B; Dang J; IsHak WW
    J Addict Med; 2017; 11(1):47-54. PubMed ID: 27763941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.
    Bobo WV; Chen H; Trivedi MH; Stewart JW; Nierenberg AA; Fava M; Kurian BT; Warden D; Morris DW; Luther JF; Husain MM; Cook IA; Lesser IM; Kornstein SG; Wisniewski SR; Rush AJ; Shelton RC
    J Affect Disord; 2011 Oct; 133(3):467-76. PubMed ID: 21601287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial.
    Leelahanaj T
    J Med Assoc Thai; 2012 May; 95 Suppl 5():S29-37. PubMed ID: 22934442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
    Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
    J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on Pharmacological Treatment for Comorbid Major Depressive and Alcohol Use Disorders: The Role of Extended-release Trazodone.
    Di Nicola M; Pepe M; Panaccione I; Moccia L; Janiri L; Sani G
    Curr Neuropharmacol; 2023; 21(11):2195-2205. PubMed ID: 37013426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.